Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Tiziana Life Sciences PLC is involved in the business of developing novel therapeutics for cancer with a focus on late-stage growth and complementary diagnostic tools, with the capability of predicting disease aggressiveness and prognosis in breast cancer patients. The group also has interests, beyond pure oncology, in the discovery and development of monoclonal antibody-based biologics used to benefit patients with inflammatory and auto-immune disorders. The company has a single reporting segment, The Research, and Development of Biotechnological and Pharmaceutical Products. Its lead compound, milciclib (TZLS-201), is a molecule which blocks the action of specific enzymes involved in cell division as well as a number of other protein kinases.
London, SW1 4LB, United Kingdom